Hayashi, Ayano
Mizuno, Kayoko
Shinkawa, Kanna
Sakoda, Kazunori
Yoshida, Satomi
Takeuchi, Masato
Yanagita, Motoko
Kawakami, Koji
Article History
Received: 11 October 2023
Accepted: 18 March 2024
First Online: 25 March 2024
Declarations
:
: This study was approved by the Ethics Committee of Kyoto University (R3141) and did not require individual consent because data were anonymized. The need for informed consent was waived by the Ethics Committee of Kyoto University. During the study, we adhered to the tenets of the Declaration of Helsinki.
: Not applicable.
: K.K has received research funds from Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mitsubishi Corporation, OMRON Corporation, Real World Data Co., Ltd., Sumitomo Pharma Co., Ltd., and Toppan Inc.; consulting fees from Advanced Medical Care Inc., JMDC Inc., LEBER Inc., and Shin Nippon Biomedical Laboratories Ltd.; executive compensation from Cancer Intelligence Care Systems, Inc.; honoraria from Chugai Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., Mitsubishi Chemical Holdings Corporation, Mitsubishi Corporation, Pharma Business Academy, and Toppan Inc.; and held stock in Real World Data Co., Ltd. S.Y has received consulting fees from Real World Data Co., Ltd. Y.M received research funds from Mitsubishi Tanabe Pharma and Boehringer Ingelheim. None of the other authors have potential conflicts of interest to declare.